Heat Biologics (Chapel Hill, NC) a clinical-stage biopharmaceutical company focused on vaccines and antibodies for non-small cell lung cancer and stimulation of regulatory T cells, closed a $2.8M Series A financing. Participants include Brightline Ventures.